IJCM  Vol.10 No.4 , April 2019
Discussion on the Effectiveness of Elevating HDL-C in Treating Cardiovascular Diseases of Patients with Type 2 Diabetes Mellitus
High density lipoprotein protects cardiovascular diseases and reduces the risk of cardiovascular diseases through cholesterol reverse transport and other mechanisms. High-density lipoprotein cholesterol (HDL-C) is an independent predictor of negative events in cardiovascular diseases. Low concentration of HDL-C indicates abnormal regulation of HDL anabolism. Various proteins and receptors such as cholesteryl ester transfer protein (CETP) are involved in HDL anabolism. Type 2 Diabetes Mullitu and its related metabolic syndrome, chronic inflammation as well as oxidative stress not only affect the proteins and receptors related to HDL anabolism, but also affect their functional changes, making HDL change from anti-inflammatory, antioxidant, protecting endothelial cell function to pro-inflammatory, pro-oxidative and pro-endothelial cell apoptosis. This article will describe the relationship between HDL-C, type 2 diabetes and cardiovascular diseases from the effects of T2DM on HDL anabolism and function, and further explore the effectiveness of elevating HDL-C in treating cardiovascular diseases of patients with type 2 diabetes.
Cite this paper: Wang, S. and Wang, L. (2019) Discussion on the Effectiveness of Elevating HDL-C in Treating Cardiovascular Diseases of Patients with Type 2 Diabetes Mellitus. International Journal of Clinical Medicine, 10, 293-305. doi: 10.4236/ijcm.2019.104022.

[1]   Kunutsor, S.K., Kieneker, L.M., Bakker, S.J.L., James, R.W. and Dullaart, R.P.F. (2017) Incident Type 2 Diabetes Is Associated with HDL, But Not with Its Anti-Oxidant Constituent—Paraoxonase-1: The Prospective Cohort PREVEND Study. Metabolism, 73, 43-51.

[2]   Yang, S.H., Du, Y. and Li, X.L. (2017) Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular Events in Diabetics with Coronary Artery Disease. The American Journal of the Medical Sciences, 354, 117-124.

[3]   Chang, T.I., Streja, E. and Moradi, H. (2017) Could High-Density Lipoprotein Cholesterol Predict Increased Cardiovascular Risk. Current Opinion in Endocrinology, Diabetes and Obesity, 24, 140-147.

[4]   Hermans, M.P., Valensi, P. and Ahn, S.A. (2018) [HDL-C/apoA-I]: A Multi-Vessel Cardiometabolic Risk Marker in Women with T2DM. Diabetes/Metabolism Research and Reviews, 34, 829-840.

[5]   Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G. and Liebisch, G. (2009) Lipidprofiling of FPLC-Separated Lipoprotein Fractions by Electrosprayionization Tandem Mass Spectrometry. The Journal of Lipid Research, 50, 574-585.

[6]   Van Linthout, S., Spillmann, F., Schultheiss, H.P. and Tschöpe, C. (2010) High-Density Lipoprotein at the Interface of Type 2 Diabetes Mullitus and Cardiovascular Disorders. Current Pharmaceutical Design, 16, 1504-1516.

[7]   Park, K.H., Shin, D.G. and Cho, K.H. (2014) Dysfunctional Lipoproteins from Young Smokers Exacerbate Cellular Senescence and Atherogenesis with Smaller Partical Size and Severe Oxidation and Glycation. Toxicological Sciences, 140, 16-25.

[8]   Shao, B., Tang, C., Sinha, A., Mayer, P.S., Davenport, G.D., Brot, N., et al. (2014) Humans with Atherosclerosis Have Impaired ABCA1 Cholesterol Efflux and Enhanced High-Density Lipoprotein Oxidation by Myeloperoxidase. Circulation Research, 114, 1733-1742.

[9]   Mackness, M. and Mackness, B. (2015) Human Paraoxonase-1 (PON1): Gene Structure and Expression, Promiscuous Activities and Multiple Physiological Roles. Gene, 567, 12-21.

[10]   Rosenson, R.S., Brewer, H.B., Davidson, W.S., Fayad, Z.A., Fuster, V., Goldstein, J., et al. (2012) Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport. Circulation, 125, 1905-1919.

[11]   Wang, X., Collins, H.L., Ranalletta, M., Fuki, I.V., Billheimer, J.T., et al. (2007) Macrophage ABCA1 and ABCG1, But Not SR-BI, Promote Macrophage Reverse Cholesterol Transport in Vivo. Journal of Clinical Investigation, 117, 2216-2224.

[12]   Rosamond, W., Flegal, K., Friday, G., et al. (2007) Heart Disease and Stroke Statistics—2007 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 115, 69-71.

[13]   Oda, M.N. (2015) High-Density Lipoprotein Cholesterol: Origins and the Path Ahead. Current Opinion in Endocrinology, Diabetes and Obesity, 22, 133-141.

[14]   Hirschler, V., Maccallini, G., Sanchez, M., Gonzalez, C. and Molinari, C. (2015) Association between Triglyceride to HDL-C Ratio and Insulin Resistance in Indigenous Argentinean Children. Pediatric Diabetes, 16, 606-612.

[15]   Rosenson, R.S., Brewer, H.B., Ansell, B.J., et al. (2016) Dysfunctional HDL and Atherosclerotic Cardiovascular Disease. Nature Reviews Cardiology, 13, 48-60.

[16]   Rosenson, R.S., Brewer Jr., H.B., Ansell, B., et al. (2013) Translation of High-Density Lipoprotein Function into Clinical Practice: Current Prospects and Future Challenges. Circulation, 128, 1256-1267.

[17]   AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., et al. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Stat in Therapy. The New England Journal of Medicine, 367, 2255-2267.

[18]   Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. (2012) Plasma HDL Cholesterol and Risk of Myocardial Infarction: A Mendelian Randomisation Study. The Lancet, 380, 572-580.

[19]   Huang, M.C., Chang, W.T., Chang, H.Y., et al. (2017) FADS Gene Polymorphisms, Fatty Acid Desaturase Activities, and HDL-C in Type 2 Diabetes. International Journal of Environmental Research and Public Health, 14, pii: E572.

[20]   Pérez-Méndez, ó., Pacheco, H.G., Martínez-Sánchez, C., et al. (2014) HDL-Cholesterol in Coronary Artery Disease Risk: Function or Structure? Clinica Chimica Acta, 429, 111-122.

[21]   Song, X., Teng, J., Wang, A., et al. (2016) Positive Correlation between Serum IGF-1 and HDL-C in Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice, 118, 44-49.

[22]   Patel, S., Puranik, R., Nakhla, S., et al. (2009) Acute Hypertriglyceridaemia in Humans Increases the Triglyceride Content and Decreases the Anti-Inflammatory Capacity of High Density Lipoproteins. Atherosclerosis, 204, 424-428.

[23]   Zhang, L., Chen, S., Deng, A., Liu, X., Liang, Y., Shao, X., et al. (2015) Association between Lipid Ratios and Insulin Resistance in a Chinese Population. PLoS ONE, 10, e0116110.

[24]   Baldan, A., Tarr, P., Lee, R. and Edwards, P.A. (2006) ATP-Binding Cassette Transporter G1 and Lipid Homeostasis. Current Opinion in Lipidology, 17, 227-232.

[25]   Mauldin, J.P., Srinivasan, S., Mulya, A., et al. (2006) Reduction in ABCG1 in Type 2 Diabetic Mice Increases Macrophage Foam Cell Formation. Biological Chemistry, 281, 21216-21224.

[26]   Barbarossa, G., Renzi, A., D’Erasmo, L., et al. (2014) The Relation between Glycemic Control and HDL-C in Type 2 Diabetes: A Preliminary Step Forward? Diabetes Research and Clinical Practice, 104, 26-28.

[27]   Uehara, Y., Engel, T., Li, Z., et al. (2002) Polyunsaturated Fatty Acids and Acetoacetate Downregulate the Expression of the ATP-Binding Cassette Transporter A1. Diabetes, 51, 2922-2928.

[28]   Chait, A., Han, C.Y., Oram, J.F., et al. (2005) Thematic Review Series: The Immune System and Atherogenesis. Lipoprotein-Associated Inflammatory Proteins: Markers or Mediators of Cardiovascular Disease? The Journal of Lipid Research, 46, 389-403.

[29]   Ina, K., Hayashi, T., Araki, A., et al. (2014) Importance of High-Density Lipoprotein Cholesterol Levels in Elderly Diabetic Individuals with Type IIb Dyslipidemia: A 2-Year Survey of Cardiovascular Events. Geriatrics & Gerontology International, 14, 806-810.

[30]   Passarelli, M., Tang, C., McDonald, T.O., et al. (2005) Advanced Glycation End Product Precursorsimpair ABCA1-Dependent Cholesterol Removal from Cells. Diabetes, 54, 2198-2205.

[31]   McGillicuddy, F.C., de la LleraMoya, M., Hinkle, C.C., et al. (2009) Inflammation Impairs Reverse Cholesterol Transport in Vivo. Circulation, 119, 1135-1145.

[32]   Sorrentino, S.A., Besler, C., Rohrer, L., et al. (2010) Endothelial-Vasoprotective Effects of High Density Lipoprotein Are Impaired in Patients with Type 2 Diabetes Mellitus But Are Improved after Extended-Release Niacin Therapy. Circulation, 12, 110-122.

[33]   Annema, W., Nijstad, N., Tolle, M., et al. (2010) Myeloperoxidase and Serumamyloid A Contribute to Impaired in Vivo Reverse Cholesterol Transport during the Acute Phase Response But Not Group IIA Secretory Phospholipase A(2). The Journal of Lipid Research, 51, 743-754.

[34]   Zerrad-Saadi, A., Therond, P., Chantepie, S., et al. (2009) HDL3-Mediated Inactivation of LDL Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipidrigidity: Relevance Toinflammation and Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 2169-2175.

[35]   Briand, F., Prunet-Marcassus, B., Thieblemont, Q., et al. (2014) Raising HDL with CETP Inhibitor Torcetrapib Improves Glucose Homeostasis in Dyslipidemic and Insulin Resistant Hamsters. Atherosclerosis, 233, 359-362.

[36]   Njajou, O.T., Kanaya, A.M., Holvoet, P., et al. (2009) Association between Oxidized LDL, Obesity and Type 2 Diabetes in a Population-Based Cohort, the Health, Aging and Body Composition Study. Diabetes/Metabolism Research and Reviews, 25, 733-739.

[37]   Liu, F. and Huang, L. (2001) Improving Plasmid DNA-Mediated Liver Gene Transfer by Prolonging Its Retention in the Hepatic Vasculature. The Journal of Gene Medicine, 3, 569-576.

[38]   Von Eckardstein, A. and Widmann, C. (2014) High-Density Lipoprotein, Beta Cells, and Diabetes. Cardiovascular Research, 103, 384-394.

[39]   Nobecourt, E., Jacqueminet, S., Hansel, B., et al. (2005) Defective Antioxidative Activity of Small Dense HDL3 Particles in Type 2 Diabetes: Relationship to Elevated Oxidative Stress and Hyperglycaemia. Diabetologia, 48, 529-538.

[40]   Kon, V., Yang, H. and Fazio, S. (2015) Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-Density Lipoprotein. Archives of Medical Research, 46, 379-391.

[41]   Mastorikou, M., Mackness, B., Liu, Y., et al. (2008) Glycation of Paraoxonase-1 Inhibits Its Activity and Impairs the Ability of High Density Lipoprotein to Metabolize Membrane Lipid Hydroperoxides. Diabetic Medicine, 25, 1049-1055.

[42]   Rozenberg, O., Shih, D.M. and Aviram, M. (2005) Paraoxonase 1 (PON1) Attenuates Macrophage Oxidative Status: Studies in PON1 Transfected Cells and in PON1 Transgenic Mice. Atherosclerosis, 181, 9-18.

[43]   Feingold, K.R. and Grunfeld, C. (2016) Effect of Inflammation on HDL Structure and Function. Current Opinion in Lipidology, 27, 521-530.

[44]   Rozenberg, O., Rosenblat, M., Coleman, R., et al. (2003) Paraoxonase (PON1) Deficiency Is Associated with Increased Macrophage Oxidative Stress: Studies in PON1-Knockout Mice. Free Radical Biology & Medicine, 34, 774-784.

[45]   Modi, K.D., Chandwani, R., Ahmed, I., et al. (2016) Discordance between Lipid Markers Used for Predicting Cardiovascular Risk in Patients with Type 2 Diabetes. Diabetology & Metabolic Syndrome, 10, 99-102.

[46]   Persegol, L., Verges, B., Foissac, M., et al. (2006) Inability of HDL from Type 2 Diabetic Patients to Counteract the Inhibitory Effect of Oxidised LDL on Endothelium-Dependent Vasorelaxation. Diabetologia, 49, 1380-1386.

[47]   Riwanto, M., Rohrer, L., Roschitzki, B., et al. (2013) Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density lipoprotein Proteome Remodeling. Circulation, 127, 891-904.

[48]   Vita, J.A., Brennan, M.L., Gokce, N., et al. (2004) Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans. Circulation, 110, 1134-1139.

[49]   van der Stoep, M., Korporaal, S.J. and Van Eck, M. (2014) High-Density Lipoprotein as a Modulator of Platelet and Coagulation Responses. Cardiovascular Research, 103, 362-371.

[50]   Feng, Y., Jacobs, F., Van Craeyveld, E., et al. (2008) Human ApoA-I Transfer Attenuates Transplant Arteriosclerosis via Enhanced Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 278-283.

[51]   Lupattelli, G., Marchesi, S., Roscini, A.R., et al. (2002) Direct Association between High-Density Lipoprotein Cholesterol and Endothelial Function in Hyperlipemia. American Journal of Cardiology, 90, 648-650.

[52]   Ren, X., Chen, Z.A., Zheng, S., et al. (2016) Association between Triglyceride to HDL-C Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus. PLoS ONE, 11, e0154345.

[53]   Hanefeld, M., Traylor, L., Gao, L., et al. (2017) The Use of Lipid-Lowering Therapy and Effects of Antihyperglycaemic Therapy on Lipids in Subjects with Type 2 Diabetes with or without Cardiovascular Disease: A Pooled Analysis of Data from Eleven Randomized Trials with Insulin Glargine 100 U/ml. Cardiovascular Diabetology, 16, 66.

[54]   Quispe, R., Martin, S.S., Jones, S.R., et al. (2016) Triglycerides to High-Density Lipoprotein-Cholesterol Ratio, Glycemic Control and Cardiovascular Risk in Obese Patients with Type 2 Diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 23, 150-156.

[55]   Oak, J.H. and Cai, H. (2007) Attenuation of Angiotensin II Signaling Recouplesenos and Inhibits Nonendothelial NOX Activity in Diabetic Mice. Diabetes, 56, 118-126.

[56]   Kong, D., Melo, L.G., Mangi, A.A., et al. (2004) Enhanced Inhibition of Neointimal Hyperplasia by Genetically Engineered Endothelial Progenitor Cells. Circulation, 109, 1769-1775.

[57]   Loomans, C.J., de Koning, E.J., Staal, F.J., et al. (2004) Endothelial Progenitor Cell Dysfunction: A Novel Concept in the Pathogenesis of Vascular Complications of Type 1 Diabetes. Diabetes, 53, 195-199.

[58]   Sharif, S., van der Graaf, Y., Nathoe, H.M., et al. (2016) HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients with Type 2 Diabetes. Diabetes Care, 39, 1424-1430.

[59]   Van Linthout, S., Riad, A., Dhayat, N., et al. (2007) Anti-Inflammatory Effects of Atorvastatin Improve Left Ventricular Function in Experimental Diabetic Cardiomyopathy. Diabetologia, 50, 1977-1986.

[60]   Vaziri, N.D. (2016) HDL Abnormalities in Nephrotic Syndrome and Chronic Kidney Disease. Nature Reviews Nephrology, 12, 37-47.

[61]   Prufer, N., Kleuser, B. and van der Giet, M. (2015) The Role of Serum Amyloid A and Sphingosine-1-Phosphate on High-Density Lipoprotein Functionality. Biological Chemistry, 396, 573-583.

[62]   Nishikawa, T., Edelstein, D., Du, X.L., et al. (2000) Normalizing Mitochondrial Superoxide Production Blocks Three Pathways of Hyperglycaemic Damage. Nature, 404, 787-790.

[63]   Westermann, D., Rutschow, S., Van Linthout, S., et al. (2006) Inhibition of p38 Mitogen-Activated Protein Kinase Attenuates Left Ventricular Dysfunction by Mediating Pro-Inflammatory Cardiac Cytokine Levels in a Mouse Model of Diabetes Mellitus. Diabetologia, 49, 2507-2513.

[64]   Dewald, O., Frangogiannis, N.G., Zoerlein, M., et al. (2003) Development of Murine Is Chemic Cardiomyopathy Is Associated with a Transient Inflammatory Reaction and Depends on Reactive Oxygen Species. Proceedings of the National Academy of Sciences of the United States of America, 100, 2700-2705.

[65]   Shen, X., Zheng, S., Metreveli, N.S., et al. (2006) Protection of Cardiac Mitochondria by Overexpression of MnSOD Reduces Diabetic Cardiomyopathy. Diabetes, 55, 798-805.

[66]   Suzuki, K., Murtuza, B., Sammut, I.A., et al. (2002) Heat Shock Protein 72 Enhances Manganese Superoxide Dismutase Activity during Myocardial Is Chemia Reperfusion Injury, Associated with Mitochondrial Protection and Apoptosis Reduction. Circulation, 106, 1270-1276.